Trial reportFemale pelvic medicine & reconstructive surgery
Minimum important differences for scales assessing symptom severity and quality of life in patients with fecal incontinence.
Trial report in Female pelvic medicine & reconstructive surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03543566 (Antimuscarinic Medication for Urgency Urinary Incontinence in Women With Dual Incontinence), which is not on this map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Antimuscarinic Medication for Urgency Urinary Incontinence in Women With Dual Incontinence (Darifenacin for Treatment of Women With Dual Incontinence)
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Tools for fecal incontinence assessment: lessons for inflammatory bowel disease trials based on a systematic review.United European gastroenterology journal · 2020Pooled it
- Home-Based Biofeedback for Fecal Incontinence: A Randomized Clinical Trial.Urogynecology (Philadelphia, Pa.) · 2026Trial
- Silicone Irregular Hexagon Pessary Versus Polyvinyl Chloride Ring Pessary for Pelvic Organ Prolapse: Randomised Controlled Trial.International urogynecology journal · 2025Trial
- Correlation Between Mobile-Application Electronic Bowel Diary and Validated Questionnaires in Women with Fecal Incontinence.International urogynecology journal · 2024Trial
- Five-year surgical outcomes of transvaginal apical approaches in women with advanced pelvic organ prolapse.International urogynecology journal · 2023Trial
- Controlling faecal incontinence in women by performing anal exercises with biofeedback or loperamide: a randomised clinical trial.The lancet. Gastroenterology & hepatology · 2019Trial
- RCT of vaginal extraperitoneal uterosacral ligament suspension (VEULS) with anterior mesh versus sacrocolpopexy: 4-year outcome.International urogynecology journal · 2018Trial
- Trial
- Perioperative Behavioral Therapy and Pelvic Muscle Strengthening Do Not Enhance Quality of Life After Pelvic Surgery: Secondary Report of a Randomized Controlled Trial.Physical therapy · 2017Trial
- Quality of Life and Sexual Function 2 Years After Vaginal Surgery for Prolapse.Obstetrics and gynecology · 2016Trial
- A Digital Therapeutic Pelvic Health System Improves Fecal Incontinence Symptoms in a Real-World Patient Cohort.Diseases of the colon and rectum · 2026Observational
- Synthetic Mesh Reconstruction Improves Pelvic Floor Function and Quality of Life After Sacrectomy: A Preliminary Clinical Assessment.Clinical orthopaedics and related research · 2025Article
- Impact of a Digital Therapeutic Device on Pelvic Floor Symptoms.Urogynecology (Philadelphia, Pa.) · 2025Article
- Comparison of the Fecal Incontinence Severity Scores between Self-administration by Patients and an Oral Interview by a Physician.Journal of the anus, rectum and colon · 2024Article
- Comparison of outcomes of laparoscopic sacrocolpopexy with concomitant supracervical hysterectomy or uterine preservation.International urogynecology journal · 2023Article
- Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field Trial.Ophthalmology and therapy · 2022Article
- Do resistance exercises during biofeedback therapy enhance the anal sphincter and pelvic floor muscles in anal incontinence?Neurogastroenterology and motility · 2022Article
- Effect of darifenacin on fecal incontinence in women with double incontinence.International urogynecology journal · 2021Observational
- Risk Factors for Surgical Failure and Worsening Pelvic Floor Symptoms Within 5 Years After Vaginal Prolapse Repair.Obstetrics and gynecology · 2020Article
- Fecal Incontinence Symptoms and Impact in Older Versus Younger Women Seeking Care.Diseases of the colon and rectum · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 1 country.
Funding
Abstract
objectivesThe objective of this study was to estimate the minimum important difference (MID) for the Fecal Incontinence Severity Index (FISI), the Colorectal-Anal Distress Inventory (CRADI) scale of the Pelvic Floor Distress Inventory, the Colorectal-Anal Impact Questionnaire (CRAIQ) scale of the Pelvic Floor Impact Questionnaire, and the Modified Manchester Health Questionnaire (MMHQ).
methodsWe calculated the MIDs using anchor-based and distribution-based approaches from a multicenter prospective cohort study investigating adaptive behaviors among women receiving nonsurgical and surgical management for fecal incontinence (FI). Patient responses were primarily anchored using a Global Impression of Change scale. The MID was defined as the difference in mean change from baseline between those who indicated they were "a little better" and those who reported "no change" on the Global Impression of Change scale 3 months after treatment. The effect size and SE of measurement were the distribution methods used.
resultsThe mean changes (SD) in FISI, CRADI, CRAIQ, and MMHQ scores from baseline to 3 months after treatment were -8.8 (12.0), -52.7 (70.0), -60.6 (90.0), and -12.6 (19.2), respectively. The anchor-based MID estimates suggested by an improvement from no change to a little better were -3.6, -11.4 and -4.7, -18.1 and -8.0, and -3.2 for the FISI, CRADI (long and short version), CRAIQ (long and short version), and MMHQ, respectively. These data were supported by 2 distribution-based estimates.
conclusionsThe MID values for the FISI are -4, CRADI (full version, -11; short version, -5), CRAIQ (full version, -18; short version, -8), and MMHQ -3. Statistically significant improvements that meet these thresholds are likely to be clinically important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.